Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins.
Saved in:
| Title: | Correction: Evaluating the pentapharmacological potency of otamixaban against lung cancer CDK2, transferase, oxidoreductase and signalling proteins. |
|---|---|
| Authors: | Baeissa HM, Bakhsh T, Shakoori AM, Sindi G, Zaki RM, Kamal MA, Alsufyani HA, Habib AH, Khayyat AIA, Rafeeq M, Jairajpuri DS |
| Source: | PloS one [PLoS One] 2026 Mar 09; Vol. 21 (3), pp. e0344592. Date of Electronic Publication: 2026 Mar 09 (Print Publication: 2026). |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0344592 |
